Abbott Laboratories2004 Fact Book

Contents

2 Financial Highlights4 Market-Leading Positions and Abbotts Leading Brands5 Rankings6 Pharmaceutical Products

10 Medical Products12 Medical Products Diagnostics13 Medical Products Abbott Molecular Diagnostics13 Medical Products Abbott Diabetes Care14 Medical Products Point-of-Care14 Medical Products Nutritionals16 Medical Products Abbott Vascular Devices17 Medical Products Spinal Concepts18 Medical Products Animal Health19 TAP Pharmaceutical Products20 Abbotts Commitment to Global Citizenship24 History26 Six-Year Financial Summary28 Plant Locations28 Directors29 Senior Management and Corporate Officers

Abbott Laboratories

Founded in 1888 by Dr. Wallace Calvin Abbott,a Chicago physician, Abbott Laboratories is a broad-based health care company that discovers,develops, manufactures and markets products and services that span the continuum of care from prevention and diagnosis to treatment and cure. Abbotts principal businesses includepharmaceuticals and medical products, includingnutritionals, devices and diagnostics.

Headquartered in north suburban Chicago,Abbott serves customers in more than 130 countries, with a staff of 55,000-plus*at more than 120 manufacturing, distribution, researchand development, and other locations.

* Prior to its spin off of Hospira on May 3, 2004, Abbottemployed more than 70,000 people worldwide.

Abbott is focused on advancing patientcare by developinginnovative solutionsin pharmaceuticals,diagnostics,medical devices and nutritionals.

3

Cash dividendsdeclared per share

2003:2002:2001:2000:1999:

$0.98 0.94 0.84 0.76 0.68

1.0

0.8

0.6

0.2

0.4

Pharmaceutical Products Group

$11.4 billion

MedicalProducts Group

$8.3 billion

U.S. Hospital Products

U.S. Nutritionals

U.S. Pharmaceuticals

Worldwide Diagnostics

Other

International

2003 Sales by DivisionTotal: $19.7 billion

In 2003, Abbott reported sales and net earnings

of $19.7 billion and $3.5 billion, respectively. Abbott

also recorded its 320th consecutive quarterly dividend

to be paid to shareholders since 1924. In addition,

2003 marked the 31st straight year Abbotts dividends

have increased. The companys Pharmaceutical

Products Group which includes U.S. pharmaceuticals,

specialty products and international sales of pharma-

ceutical, nutritional and hospital products generated

sales of more than $11 billion. The Medical Products

Group which includes worldwide diagnostics, U.S.

hospital products and U.S. nutritionals generated

more than $8 billion in sales.

Abbotts leadership positions in several multibillion-

dollar businesses provide a unique balance of revenue

growth opportunities and cash flow sources that

allow the company to invest in its future. To further

strengthen its business and sustain its success, Abbott

invested more than $1.7 billion in R&D in 2003.

During 2003, Abbotts operating cash flow was $3.7

billion. The company plans to continue to use its

strong cash flow to support its dividend policy, repay

debt and buy back stock under the companys share

repurchase program.

2

Financial Highlights

Research and development

2003:2002:2001:2000:1999:

$1.7 1.6 1.6 1.4 1.2

2.0

1.5

1.0

0.5

(dollars in billions)

Net sales worldwide

2003:2002:2001:2000:1999:

$7.9 6.9 6.2 5.1 5.1

.

$11.8 10.8 10.1 8.6 8.1

..

$19.7 17.7 16.3 13.7 13.2

20

15

10

5

(dollars in billions)

4 5

FortuneRanked 96th on the Fortune 500 list of the largest U.S.-based corporations (ranked by 2003 revenue).

Recognized as one of the Most Admired Companiesin the pharmaceutical sector every year since 1984.

Ranked among the 50 Best Companies for Minoritiesin the United States for the sixth consecutive year.

ForbesRanked 121 on the Forbes 2000 list.(ranked by sales, profits, assets and market value).

HealthSelected as one of the 10 Best Companies for Women.

MoneyNamed one of Americas Best Stocks.

Working MotherNamed one of the 10 Best Employers for Mothers.

R&D DirectionsNamed one of the 10 Best Pipelines.

Market-Leading Positions and Abbotts Leading Brands

Rankings

Abbott is ranked among the top companies in the world for financialstrength and workplace excellence byleading national publications, including:

Ensure, Glucerna, ZonePerfect

-

Biaxin / Biaxin XL / Klacid / Klaricid Omnicef

Flomax

AbbottPrism systemViral screening reagents

TriCor

MediSense Precision Xtra MediSense Precision PCx

TheraSense FreeStyleTheraSense FreeStyle Flash

Cell-Dyn systems and reagents

AxSym system and reagents

Humira

Similac AdvanceIsomil Advance

Ultane / Sevorane

Depakote / Depakote ER

Kaletra, Norvir

Zemplar

Synthroid

Perclose products

Abbotts Pharmaceutical Products Group aims to create a top-tier globalpharmaceutical business one that isdedicated to discovering, developing and marketing breakthrough drugs thatimprove patient health. The groups primary focus is on translating innova-tive science into effective medicine.

6

Pharmaceutical Products Group

7

8 9

AIDS/Anti-virals. Drugs to treat HIV/AIDS.

Kaletra (lopinavir/ritonavir) Advanced-generation protease inhibitor for the treatment of HIV/AIDS.

Norvir (ritonavir) Protease inhibitor for the treatment of HIV/AIDS.

Anti-infectives. Antibiotics for the treatment of respiratory infectionsand skin infections.

Biaxin, Klacid, Klaricid Macrolide antibiotic for the treatment of upper and(clarithromycin) lower respiratory tract infections, and skin and skinBiaxin XL, Klaricid OD structure infections; treatment and prevention of(extended-release formulation) Mycobacterium avium complex (MAC); and

eradication of the ulcer-causing bacterium H. pylori.

Erythromycin, PCE Generic and polymer-coated antibiotic.

Omnicef (cefdinir) An oral cephalosporin antibiotic for the treatment of a wide range of infections, including chronic bronchitis, ear infections, pneumonia, sinus infections, and throat and tonsil infections.

Cardiovascular. Includes anti-hypertensive medicines for reducinghigh blood pressure and medicine for reducing high cholesterol and triglycerides.

Blopress, Tiadyl (candesartan) Angiotension-2 antagonist for hypertension.

Mavik (trandolapril) and Long-acting angiotensin-converting enzyme (ACE)Tarka (trandolapril/verapamil) inhibitor, and combination of ACE inhibitor and

calcium channel blocker, respectively.

Micardis (telmisartan) Angiotension-2 antagonist for hypertension.*

TriCor (fenofibrate) Cholesterol- and triglyceride-reducing agent.

Abbokinase (urokinase) Injectable pharmaceutical agent that dissolves blood clots in the treatment of pulmonary embolism.

Gastrointestinal. Drugs to treat diseases of the GI track.

Prevacid, Ogastro Proton pump inhibitor for gastroesophageal reflux(lansoprazole) disease (GERD), ulcers and other diseases

characterized by excess stomach acid. (Marketed inthe United States by TAP Pharmaceutical Products Inc.)

Immunology. Drugs used to treat diseases of the immune system,including rheumatoid arthritis.

Humira (adalimumab) Fully human monoclonal antibody for rheumatoid arthritis.

Metabolic Disease. Includes medicines for the management of obesityand the treatment of thyroid disease.

Meridia, Reductil (sibutramine Serotonin and norepinephrine re-uptake inhibitorhydrochloride monohydrate) (SNRI) for the management of obesity.

Synthroid Synthetic thyroid hormone for the treatment of(levothyroxine sodium) hypothyroidism.

Neuroscience and Pain. Drugs to treat neurological conditions, as well as medications for pain management.

Depakote, Epival, Valcote Anti-epileptic agent also used for the treatment of(divalproex sodium) the manic phase of bipolar disorder and for theDepakote ER prevention of migraine headaches. Extended-release,(extended-release once-daily formulation for the treatment offormulation) epilepsy (adult/pediatric) and the prevention of

migraine headaches.

Mobic (meloxicam) Preferential COX inhibitor to treat pain from rheumatoid arthritis and osteoarthritis.**

Dilaudid (hydromorphone Analgesic for moderate-to-severe pain.hydrochloride)

Vicodin (hydrocodone/ Analgesic for moderate-to-severe pain.acetaminophen)

Vicoprofen (hydrocodone/ Analgesic for acute pain.ibuprofen)

Pediatric and Neonatal Pharmaceuticals. Drugs for serious respiratory conditions.

Survanta (beractant) Lung surfactant used to treat and prevent respiratory distress syndrome (RDS) in premature newborns.

Synagis (palivizumab) Monoclonal antibody for the prevention of serious respiratory syncytial virus (RSV) infection.

Perioperative and Intensive Care Pharmaceuticals. Provides injectableinhalation anesthetic agents, neuromuscular blockers, sedatives andother analgesic pain therapies.

Mivacron (mivacurium Cl) Neuromuscular blockers used as adjuncts to generalNimbex (cisatracurium besylate) anesthesia. These products can be used prior toNuromax (doxacurium Cl) surgery to ease endotracheal intubation and duringand Tracrium surgery to facilitate skeletal muscle relaxation and(atracurium besylate) mechanical ventilation.

Sevorane, Ultane Unique inhalation anesthetic for both inpatient and(sevoflurane) outpatient procedures, for adult and pediatric use.

Simdax (levosimendan) Injectable for acute congestive heart failure.(Marketed outside the United States.)

Renal Care Pharmaceuticals. Injectable vitamin D agent developed totreat patients with complications of end-stage renal disease.

Zemplar Next-generation therapy for the prevention and(paricalcitol injection) treatment of secondary hyperparathyroidism

associated with chronic renal failure.

Urology and Reproductive Health. Includes medicines for benign prostatic hyperplasia (BPH), advanced prostate cancer, endometriosis,anemia associated with uterine fibroids, and central precocious puberty.

Flomax (tamsulosin HCl) Alpha blocker for the treatment of BPH.*

Hytrin (terazosin HCl) Once-a-day alpha blocker for hypertension and symptoms of BPH.

Lupron, Lucrin Synthetic hormone for the treatment of advanced(leuprolide acetate) prostate cancer, endometriosis, anemia caused by

fibroid tumors (in combination with iron), and central precocious puberty. (Marketed in the United States by TAP Pharmaceutical Products Inc.)

Pharmaceutical ProductsAbbott sells pharmaceutical products in key therapeutic areas throughseveral divisions, including the Pharmaceutical Products Division, theRoss Products Division, and Abbott International.

*Marketed in the United States through an alliance with Boehringer Ingelheim Pharmaceuticals. ** Marketed in the United States and Latin America through an alliance with Boehringer Ingelheim Pharmaceuticals.

Abbotts Medical Products Group hasbuilt leading businesses in diagnostictesting and instrumentation;hospital-based devices; and nutritionalproducts for children and adults.The group is committed to developinginnovative, highly differentiated products for patients and consumers.

10

Medical Products Group

11

12 13

Immunoassay and Clinical Chemistry. Includes systems and assays tomeasure a variety of analytes found in the blood and to diagnose andmonitor diseases and therapies. Also includes blood screening instru-mentation and assays used to ensure the safety of the blood supply.

AbbottPrism Fully automated analyzer specifically designed for high-volume blood centers and blood banks to screen donated blood for multiple viral assays. Menu includes HIV, hepatitis and HTLV assays. (Marketed outside the United States.)

Aeroset and c8000 High- and medium-volume clinical chemistry analyzers with broad testing menus to facilitate routine and specialty testing.

Architect i2000, i2000SR, Modular analyzers that provide immunoassay andci8200 and i4000 clinical chemistry results. Menu includes tests for

cancer, thyroid, fertility, anemia and pregnancy.

AxSym Automated immunoassay analyzer with continuous access and STAT capabilities. Menu includes tests for cancer, cardiovascular, drugs of abuse, fertility,pregnancy and thyroid.

IMx Automated benchtop analyzer for immunoassay testing. Menu includes tests for thyroid, cancer,fertility and cardiovascular markers.

TDx and TDx Flx Automated benchtop analyzers for monitoring therapeutic drug levels. Menu includes theophylline,vancomycin, drugs of abuse and thyroid tests.

Determine Self-contained test strips for use by a wide range ofhealth care professionals. Menu includes tests for HIV, hepatitis and syphilis. (Marketed outside the United States.)

OraQuick Rapid, simple, whole-blood test for HIV. (Marketed in the United States in collaboration with OraSure Technologies, Inc.)

Hematology. Abbott develops, manufactures and markets Cell-Dynhematology systems used to perform sophisticated blood cell analysis.

Cell-Dyn 4000, 3700, A complete line of highly automated hematology3200 and 1800 analyzers to meet the testing needs of any laboratory,

whether high or low volume.

Abbott Molecular Diagnostics technology provides physicians withcritical information based on the detection of subtle changes inpatients genes and chromosomes allowing for earlier detection,selection of appropriate therapies and monitoring of disease-progression. Includes instruments and reagents used to conductsophisticated analysis of patient DNA and RNA. In 2002, Abbottformed an alliance with Celera Diagnostics to develop and marketnovel molecular diagnostic products.

LCx Easy-to-use benchtop analyzer for detecting viruses such as HIV at levels undetectable by other technologies. (Marketed outside the United States.)

PathVysion HER-2 DNA-based tests that detect the HER-2/neu gene inDNA Probe Kit breast cancer patients. Patients testing positive for

this gene are candidates for treatment with Herceptin, a targeted monoclonal treatment.

UroVysion A DNA-based test for monitoring recurrence ofbladder cancer. Provides early detection through the identification of genetic changes.

ViroSeq HIV-1 A sequencing-based testing method for accurateGenotyping System identification of known drug-resistant HIV-1

mutations. (Marketed by Abbott as part of the Celera Diagnostics alliance.)

Medical Products DiagnosticsThe Medical Products Group offers a broad range of innovative instruments and tests across key segments in the global diagnosticsmarket, including hospitals, reference laboratories, blood banks,physicians offices, and clinics. Abbott Diagnostics provides a broadportfolio of products to serve clinical laboratory customers worldwide.

Medical Products Abbott Molecular Diagnostics

Abbott Diabetes Care is committed to providing innovative hand-held systems to assist patients and health professionals in the management of diabetes. Includes hand-held glucose monitors andbiosensor-based strips that offer patients convenient, accurate and fast results.

Precision PCx A hand-held, point-of-care blood glucose testing system developed to meet the unique testing and datamanagement needs of the hospital. Version 2.2.1 offers improved data communication speeds and an end-fill strip technology.

Precision Q.I.D. A small, lightweight glucose monitor designed not to start until a sufficient blood sample is detected.

Precision Xtra and First hand-held monitor to offer ketone testingPrecision Xtra Luminous capabilities; the Luminous monitor offers added

lighting features.

FreeStyle A leading blood glucose monitoring system, which allows patients reduced pain through alternate-site testing and a small (0.3 microliter) sample size.

FreeStyle Flash The worlds smallest blood glucose monitor that returns an accurate reading in just seven seconds with a 0.3 microliter sample. The Flash monitor offers unique lighting features.

FreeStyle Tracker Combines a blood glucose meter, diabetes manager,and personal digital assistant (PDA) all in one compact device.

Medical Products Abbott Diabetes Care

14 15

Pediatric Nutritionals. Abbott develops products that support thegrowth and development of infants and children, and makes theseproducts available in innovative, consumer-friendly packaging.Specialty formulations include products for premature and low-birthweight infants; products for infants and children with special tolerance or nutritional needs; hypoallergenic formulations for infantsand children with multiple food allergies or severe gastrointestinalimpairment; and a line of products for infants and children withmetabolic diseases.

Alimentum Advance Formula for infants with food allergies or colic due to protein sensitivity. Alimentum Advance is supplemented with DHA and ARA, two fatty acids found in breast milk that are important for brain andvisual development.

EleCare Nutritional formula for infants and children with multiple food allergies or severe gastrointestinal impairment.

Formance Nutritional supplement for expectant mothers.

Gain and Grow A line of follow-on formulas for children 6 months to 18 months (Gain) and up to 7 years (Grow).

Isomil Brand A broad line of soy-based formula for infants with common feeding problems. Isomil Advance with Iron is supplemented with DHA and ARA, two fatty acids found in breast milk that are important for brain and visual development, Isomil DF (for dietary management of diarrhea for infants 6 months or older), and Isomil 2 Advance (follow-on formula for babies and toddlers of ages 9 months to 24 months).

Similac Special Specialized infant formulas designed for prematureCare Advance and and low-birth-weight babies. Special Care AdvanceSimilac NeoSure Advance and NeoSure Advance are supplemented with DHA

and ARA, two fatty acids found in breast milk that are important for brain and visual development.

Pedialyte Oral electrolyte maintenance solution to help preventdehydration by quickly replacing fluids and electrolytes lost during diarrhea and vomiting. Also available as Pedialyte Freezer Pops and Pedialyte Singles.

PediaSure Complete, balanced nutritional formula in a variety of flavors for children ages 1 to 10 years. Available with fiber, as an oral supplement, and in a tubefeeding formulation.

Similac Brand A complete line of next-generation infant formulas that have added nucleotides to help support immune system development. Includes Similac Advance and Similac Lactose Free Advance (an alternative to standard milk-based formulas); supplemented with DHA and ARA, two fatty acids found in breast milk that are important for brain and visual development.Similac 2 Advance is a follow-on formula for babies and toddlers 9 months to 24 months also containing DHA and ARA.

Similac Human Milk Fortifier A nutritional supplement to add to preterm human milk for low-birth-weight infants.

Adult Nutritionals. Abbott offers a broad selection of products thatprovide complete, balanced nutrition for healthy adults, as well as medical food products for people with special dietary needs due to diabetes, cancer-induced weight loss, renal disease or respiratory conditions. Abbott also offers medical nutritionals for patients needingsupplements or requiring tube feeding.

Companion, Embrace, Complete line of enteral feeding pumps, tubesFlexiflo, Patrol and Quantum and devices.

Ensure A broad line of leading adult nutritionals, providing a source of complete, balanced nutrition. Ensureliquid and bars are available in a variety of flavors and specialized formulas. The product line includes Ensure, Ensure Plus (a higher calorie concentration),Ensure High Protein, Ensure Fiber with FOS, and Ensure High Calcium.

Glucerna The leading brand of specialized nutritional productsfor patients with diabetes. Available as shakes, meal bars, snack bars, and tube feeding formulations.Glucerna Weight Loss Shake is the first weight loss shake designed for people with diabetes.

Jevity Fiber-fortified, high-protein liquid formula for both short- and long-term tube feeding.

Nepro and Suplena Specialized nutritional products for people with kidney disease.

Optimental A ready-to-feed elemental nutritional formula for patients with malabsorptive conditions, such as Crohns disease, metabolic stress, or acute trauma.

Osmolite An isotonic, low-residue liquid formula providing complete, balanced nutrition.

Oxepa and Pulmocare Specialized nutritional products for patients with respiratory conditions, including acute lung injury (Oxepa) and pulmonary disease (Pulmocare).

ProSure Specialized nutrition and energy product clinically shown to promote weight gain, help build muscle and improve the quality of life for people with cancer-induced weight loss.

ZonePerfect A leading brand of convenient, portable nutritional products developed to satisfy hunger through a unique balance of carbohydrates, protein, and fat.Available as bars, shakes, and prepared meals.

Medical Products Point-of-CareAbbotts Point-of-Care business provides health care professionalsimmediate access to accurate, critical diagnostic test results at thepoint of patient care.

i-STAT A market-leading system comprising a hand-held analyzer and a number of single-use disposable cartridges that include panels of tests for electrolytes,metabolytes, blood gases, coagulation, and cardiac markers that deliver results in a few minutes at the patients bedside.

Medical Products NutritionalsAbbotts Ross Products Division is a leader in providing trusted pediatric nutritionals, adult nutritionals and related health care products that advance peoples quality of life. Ross develops and markets nutritional products for the United States, while AbbottInternational markets these products outside the United States.

16 17

Biologics. Includes allograft and synthetic bone void filler to provideplatform for fusion and bone regeneration.

Cerasorb A resorbable, synthetic bone void filler that promotesbone remodeling over time.

Natural Selection A line of allograft (donor bone) spacers used to restore height between the vertebral bodies of the cervical and lumbar spine.

Cervical Systems. Includes a full line of anterior and posterior cervical options.

SC-AcuFix A line of anterior cervical plates that facilitates fusionof cervical vertebrae. Includes the SecureRing mechanism to prevent bone screw disengagement.

Ant-Cer Used for dynamic stabilization of the cervical spine.

CFix Cable fixation system that allows for easy retightening to apply a precise amount of tension in the spine.

OctaFix Internal fixation system for immediate stability within the occipital cervical fixation junction.

Nex-Link A versatile technology used to stabilize the posterior cervical and upper thoracic spine.

Interbody Systems. Includes anterior column spacers that can beinserted in a variety of anterior or posterior approaches.

Harmony A common platform of disc preparation instruments used with all Spinal Concepts posterior lumbar interbody fusion spacers.

Cadence Ti A device that is implanted in the Cadence Vue thoracolumbar spine using a posterier approach.

Fortitude Ti A device that is implanted through an Fortitude Vue anterior approach.

TraXis Ti An alloy spacer used with a transforamenal TraXis Vue (oblique) approach to restore height in the vertebral

bodies of the thoracolumbar spine. (A lumbar interbody fusion spacer outside the United States.)

InFix A modular titanium device that is implanted throughan anterior approach. The device is novel in that it is assembled within the disc space, can be designed to approximate the specific patients anatomy, and is able to load the internal graft material while protecting it from excessive strain.

Medical Products Spinal ConceptsSpinal Concepts, an innovative leader in spinal implant technology,offers surgeons a unique product portfolio with technologicallyadvanced devices for the cervical, thoracic and lumbar spine.

Medical Products Abbott Vascular DevicesAbbott Vascular Devices markets a portfolio of coronary and endovascular technologies, vessel closure devices, and pharmaceuticalsused in the treatment of cardiovascular conditions.

Asahi Guidewires A full product line of PTCA guidewires that facilitate access to diseased vessels and deliver interventional tools and devices.

BiodivYsio A line of polymer-coated stents. Includes the SV stentdesigned for small vessels and the OC stent, which offers increased flexibility.

Chito-Seal A topical hemostasis pad (patch) used to expedite clot formation and to accelerate hemostasis after vessel closure procedures.

Dexamet SV Drug-eluting stent that combines dexamethasone with an innovative coating designed to mimic the bodys chemistry. (Marketed outside the United States.)

EmboShield A device with a differentiated distal protection filter used to capture emboli dislodged during coronary stenting procedures. (Marketed outside the United States.)

EmboShield Cerebral A peripheral embolic protection device with aProtection Device and differentiated distal protection filter and a carotidXact Stent System stent. The Emboshield device is used to capture

emboli dislodged during carotid stenting with the Xact stent. (Marketed outside the United States.)

Fox PTA Catheter A balloon catheter system that is designed to dilate narrowed peripheral arteries. A low profile, tapered tip, and hydrophilic coating provide for excellent deliverability to the lesion.

Jostent GraftMaster A unique and innovative covered stent graft marketedin the United States as a humanitarian device.*

Jography A portfolio of catheters with specialized tips and extra large lumens designed to optimize angiographicresults during diagnostic procedures.

Perclose A-T Suture-mediated vessel closure device that features automated knot-tying to expedite the closure process.

The Closer S (with snared Minimally invasive devices that automate the surgicalknot pusher, clincher and closure of blood vessels.suture trimmer)

Xceed A Nitinol self-expanding biliary stent system with a proprietary delivery system that offers its users placement accuracy with single-handed deployment.

Xpert A self-expanding biliary stent system that offers the lowest profile of any self-expanding biliary stent on the market.

*Humanitarian Device. Authorized by U.S. federal law for the use in the treatment of free perforations,defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts >2.75 mm in diameter. The effectiveness of this device for this use has not been demonstrated.

18 19

TAP Pharmaceutical Products

TAP Pharmaceutical Products Inc. was

established in 1977 as a joint venture between

Abbott and Takeda Chemical Industries, Ltd. of

Japan. The company is unique in that it does not

have its own internal discovery or manufacturing

organizations. Instead, the company partners

with outside organizations to develop new

compounds. The company applies its expertise

in research and development, quality assurance,

and sales and marketing to help bring to market

leading products that improve peoples lives.

TAP focuses its drug development in three major

areas: gastroenterology, urology and womens

health. The company develops and markets

pharmaceuticals for sale in the United States and

Canada, and licenses international rights for

some of these products to Abbott International.

TAPs current products include Prevacid

(lansoprazole), a proton pump inhibitor for

gastroesophageal reflux disease (GERD), ulcers

and other acid-related disorders; and Lupron

(leuprolide acetate) for the treatment of advanced

prostate cancer, endometriosis, anemia caused

by fibroid tumors (in combination with iron),

and central precocious puberty. In 2003, both

products were leading drugs in their classes and

among the top-selling drugs overall in the

United States, with combined 2003 sales of

nearly $4 billion.

Thoracolumbar Systems. Includes pedicle screw fixation options tomeet various surgical philosophies.

BacFix Thoracolumbar screw, hook and rod system utilizing a simple and efficient taper lock technology to stabilize the spine.

InCompass Thoracolumbar spinal fixation system designed to provide superior fixation with the benefits ofreduced implant volume, lower profile and easier construct assembly.

Access Dilation Port Series of dilators that gently pushes aside soft tissue for a minimally invasive approach to microdiscectomy.

PathFinder A minimally invasive pedicle screw system that may reduce blood loss and recovery time.

SpeedLink Easy to use, low profile and completely adjustable transverse connector that precisely attaches to rods using an integral cam locking mechanism.

Bone Plates. Provides a wide variety of bone plates to stabilize smallbones of the hand and foot.

Unison A line of plates that offers internal fixation for immediate stability to achieve bone fusion.

PropoFlo (propofol) Intravenous anesthetic for induction and maintenance.

SevoFlo (sevoflurane) Inhalant anesthetic, which provides veterinarians rapid induction of anesthesia and excellent control during the maintenance phase of anesthesia.

CliniCare A ready-to-feed liquid nutritional supplement for cats and dogs. Appropriate for tube, syringe and bowl feeding methods.

HemaBlock Hemostatic agent (microporous polysaccharide beads) made from natural starches that typically clotswithin 30 seconds and is eventually broken down by body enzymes within seven days. It can be used in many bleeding sites, including dental procedures and tumor biopsies.

Nexaband S/C Adhesive A medical-grade tissue adhesive that can be used instead of sutures and staples to close incisions.It provides a flexible barrier during healing and eases away naturally within seven to 10 days.

Medical Products Animal HealthAbbotts Animal Health Division is a leader in perioperative healthcare for the veterinary market. Products include anesthetic and woundcare products; nutritionals; a complete line for I.V. fluid therapy; andother veterinary critical care products.

20

Abbotts Commitment to Global Citizenship

Global citizenship reflects how Abbott

advances its business objectives;

engages its stakeholders; implements

its policies; applies its social investment

and philanthropy; and exercises its

influence to make a productive

contribution to society. Being socially

responsible extends to all aspects of

how we operate from ethics and

compliance, product quality, diversity

in the workplace, environment, health

and safety, to employee volunteerism.

Our programs reflect an engagement

and partnership with many organiza-

tions in the pursuit of sustainable

solutions to challenges facing the global

community. For more information,

see www.abbott.com/citizenship.

21

22 23

Abbotts Commitment to Global Citizenship

Corporate Governance

Abbott has a long tradition of strong financial controls and corpo-

rate governance. Ten of the 13 members on the board of directors

are independent directors. The chairs and members of the boards

Audit Committee, Compensation Committee, Public Policy

Committee, and Nominations and Governance Committee are

independent directors.

Ethics and Compliance

Ethical leadership is part of Abbotts management culture. The

companys Code of Business Conduct guides employees on ethical

and legal issues, and the Office of Ethics and Compliance provides

employees with a number of resources, including an Ethics and

Compliance Helpline, division level compliance staff, and exten-

sive in-person and web-based training programs.

Diversity and Inclusiveness

Consistent with building a high performance organization, Abbott

works to create an inclusive work environment and an employee

population that reflects the diverse marketplace it serves. Diversity

and inclusiveness are reflected in our companys polices and prac-

tices, ranging from recruitment, professional development, flexible

work arrangements, to the advancement of women and minorities

in leadership positions.

Environment, Health and Safety

Abbott has an established environment, health and safety policy

and management system to minimize the companys impact on

the environment and to create a safe workplace for our employees.

EHS programs address a number of areas, including conservation,

energy use, waste management, ergonomics, occupational health

and fleet safety.

Product Donations

Abbott works with a number of international agencies to deliver

pharmaceutical, nutritional, and hospital products in support of

medical missions, disaster relief efforts, and other humanitarian

programs around the world.

Global Care Initiatives

Abbott Access

Abbott provides HIV medicines at a loss and rapid HIV tests at

no profit to the company to developing countries hardest hit by

HIV/AIDS. For more information, see www.accesstohivcare.org.

Determine HIV Rapid Test Donation Program

Abbott donates rapid HIV tests to programs working to

prevent mother-to-child transmission of HIV in 68 developing

countries. For more information, see www.pmtctdonations.org.

Step Forward for the worlds children

The Abbott Laboratories Fund, through the Step Forward

program, is improving the lives of orphans and vulnerable

children affected by HIV/AIDS in the developing world.

For more information, see www.stepforwardforchildren.org.

Tanzania Care

Abbott and the Abbott Laboratories Fund are working with the

government of Tanzania to strengthen the countrys health care

infrastructure and systems to expand access to quality care for

people living with HIV/AIDS. For more information, see

www.tanzaniacare.org.

U.S. Product Access Programs

Patient Assistance Program

Abbott provides medicines free of charge to thousands of patients

who are uninsured, financially disadvantaged and ineligible for

publicly funded drug coverage.

Humira Medicare Assistance Program

Abbott provides Humira, its novel rheumatoid arthritis medicine,

at no cost to Medicare-eligible patients without prescription drug

coverage. For more information, see www.humira.com.

Together Rx Program

Founded by Abbott and six other major pharmaceutical compa-

nies, the Together Rx discount program offers qualified Medicare

patients discounts on more than 170 medicines. For more infor-

mation, see www.together-rx.com.

History

1888 Dr. Abbott begins producing dosimetric granules in his apartment on

Chicagos North Side.

1900 The business is officially incorporated in Illinois as the Abbott

Alkaloidal Company.

1915 The company changes its name to Abbott Laboratories.

1920 Dr. Abbott breaks ground for a new manufacturing facility in

North Chicago, Ill.

1929 Abbott stock is listed on the Chicago Stock Exchange. The offering

is 20,000 shares for $32 each.

1931 Abbott establishes its first international affiliate in Montreal, Canada.

The companys international presence will grow steadily.

1936 Abbott introduces the anesthetic agent Pentothal, developed by Abbott

scientists Drs. Ernest Volwiler and Donalee Tabern. For this discovery, they

are named to the U.S. Inventors Hall of Fame in 1986.

1941 Abbott is one of the five pioneers in the United States to start

commercial production of penicillin.

1952 Erythrocin, a new antibiotic with good activity against gram-positive

bacteria, is introduced.

1962 Abbott enters a joint venture with Dainippon Pharmaceutical Co.,

Ltd., of Osaka, Japan, to manufacture radiopharmaceuticals.

Major plant expansions are completed in England, Italy and France.

1964 The company merges with M&R Dietetic Laboratories, of Columbus, Ohio,

which eventually becomes Abbotts Ross Products Division.

1965 Abbott moves major operations to Abbott Park, a 420-acre site

southwest of its North Chicago headquarters.

1973 Abbott forms its diagnostics division to bring together all diagnostic

products and services. The company also introduces Ensure, the first

adult medical nutritional.

1977 TAP Pharmaceuticals, now known as TAP Pharmaceutical

Products Inc., is formed as a joint venture between Abbott and

Takeda Chemical Industries, Ltd.

1980 Abbott acquires Sorenson Research of Salt Lake City, Utah, which

makes innovative medical disposables.

1983 In Japan, Abbott merges three facilities into one unified health care company

called Dainabot, K.K. Depakote, a new treatment for epilepsy, is approved

in the United States.

A tradition of innovation

More than a century ago, 30-year-old Wallace C.Abbott, M.D., began making a new form ofmedicine. Using the active or alkaloid part of a medicinal plant, he formed tiny pills,called dosimetric granules, which provided ameasured amount of the drug. The demand forthese accurate granules soon far exceeded theneeds of his own practice. From a small operation based above Dr. Abbotts pharmacy,Abbott Laboratories has evolved into one ofthe worlds leading health care companies.

1985 Abbott wins U.S. approval to market the worlds first diagnostic test for AIDS,

and launches ADD-Vantage, a unique I.V. drug-delivery system. TAP receives

approval for Lupron, a new therapy for prostate cancer.

1987 Hytrin (terazosin), a new cardiovascular drug for the treatment of

hypertension, receives FDA approval.

1988 Abbott celebrates its centennial. The IMx immunoassay system is introduced

and goes on to become one of the best-selling new products in Abbotts history.

1990 Biaxin, an important new macrolide antibiotic, is introduced.

1991 Several major products are introduced worldwide, including Survanta, for

the treatment of neonatal respiratory distress syndrome. Abbott enters the

hematology testing market with the acquisition of Sequoia-Turner Corp.

1993 Hytrin receives FDA clearance for use in treating symptoms of benign

prostatic hyperplasia, a condition of the prostate. Abbott launches

AxSym, a new, labor-saving diagnostic system.

1994 Abbott introduces sevoflurane, the first truly universal anesthetic, and

completes an agreement to cross-license LCR and PCR, two gene

amplification technologies.

1995 TAP receives approval for Prevacid, a proton pump inhibitor used in

treating ulcers. AbbottPrism, the first fully automated, high-volume

blood analyzer, is introduced outside the United States.

1996 The company receives FDA clearance for Norvir, a protease inhibitor for the

treatment of HIV and AIDS. The company enters the glucose testing market

with its acquisition of MediSense, Inc.

1997 Abbott acquires the parenteral products business of Sanofi Pharmaceuticals,

Inc., and also launches several new products, including an improved version

of Similac infant formula in the United States.

1998 Abbott launches Glucerna shakes and snack bars, specially formulated

nutritionals for people with diabetes. Depakote surpasses lithium as the

most-prescribed drug for treating mania. Abbott launches several

pharmaceutical products, including Zemplar, TriCor and Synagis.

1999 Abbott launches Architect, a next-generation diagnostic system, and acquires

Perclose, Inc., a leading vascular closure devices company.

2000 Abbott receives FDA approval for several new drugs or line extensions,

including Kaletra (an advanced-generation protease inhibitor for the

treatment of HIV/AIDS), Biaxin XL (a once-daily version of its flagship

antibiotic), and Depakote ER (for migraine prevention).

2001 Abbott completes the acquisition of the pharmaceutical business of

BASF, including the global operations of Knoll Pharmaceuticals.

In addition, Abbott acquires Vysis, Inc., a leading genomic disease

management company.

2002 Abbott receives FDA approval for Humira (for rheumatoid arthritis),

Synthroid (for hypothyroidism) and Abbokinase (for pulmonary embolism).

The company launches Similac Advance, Isomil Advance and NeoSure Advance

infant formulas in the United States. Abbott acquires the cardiovascular stent

business of Biocompatibles International plc.

2003 Abbott launches three new immunodiagnostics systems on the Architect

platform. Abbott receives European regulatory approval for Humira.

Ross launches Glucerna Weight Loss Shake. The company launches the

MediSense Precision PCx 2.2.1 system worldwide. Abbott acquires JOMEDs

coronary and peripheral intervention business lines, Spinal Concepts, Inc.,

ZonePerfect Nutritional Company, and Integrated Vascular Systems, Inc.

The company announces the spin-off of much of its core hospital products

business into a new public company, to be named Hospira.

2004 Abbott acquires I-STAT Corp. and TheraSense, Inc. Hospira spins off from

Abbott, becoming one of the largest global specialty pharmaceutical and

medication delivery companies serving the hospital.24 25

26 27

Year Ended December 31 2003 2002 2001 2000 1999 1998

Summary of Operations:

Net Sales $19,680.6 17,684.7 16,285.2 13,745.9 13,177.6 12,512.7

Cost of products sold $9,473.4 8,506.3 7,748.4 6,238.6 5,977.2 5,406.6

Research and development (1) $1,733.5 1,561.8 1,577.6 1,351.0 1,194.0 1,228.8

Selling, general and administrative $5,050.9 3,978.8 3,734.9 2,894.2 2,857.1 2,759.8

Operating earnings (1) $3,322.5 3,530.1 1,894.0 3,400.6 3,149.4 3,117.6

Interest expense $188.1 238.9 307.3 113.9 144.7 160.0

Interest income $(42.0) (33.7) (72.6)) (90.7)) (62.9)) (57.4))

Other (income) expense, net $(558.0) (348.5)) (223.9)) (439.1)) (329.3 (226.8)

Earnings before taxes (1) $3,734.4 3,673.4 1,883.1 3,816.4 3,396.9 3,241.9

Taxes on earnings $981.2 879.7 332.8 1,030.4 951.1 907.5

Net earnings $2,753.2 2,793.7 1,550.4 2,786.0 2,445.8 2,334.4

Basic earnings per common share $1.76 1.79 1.00 1.80 1.59 1.52

Diluted earnings per common share $ 1.75 1.78 .99 1.78 1.57 1.50

Financial Position:

Working capital $2,650.9 2,119.6 492.4 3,078.7 1,903.0 623.9

Long-term investment securities $406.4 250.8 647.2 638.0 954.8 967.8

Net property and equipment $6,281.8 5,828.1 5,551.5 4,816.9 4,770.1 4,742.9

Total assets $26,715.3 24,259.1 23,296.4 15,283.3 14,471.0 13,259.9

Long-term debt $3,452.3 4,274.0 4,335.5 1,076.4 1,336.8 1,339.7

Shareholders investment $13,072.3 10,664.6 9,059.4 8,570.9 7,427.6 5,753.6

Return on shareholders investment %23.2 28.3 17.6 34.8 37.1 43.3

Book value per share $8.36 6.82 5.83 5.54 4.80 3.76

Other Statistics:

Gross profit margin %51.9 51.9 52.4 54.6 54.6 56.8

Research and development to net sales %8.8 8.8 9.7 9.8 9.1 9.8

Net cash from operating activities $3,746.4 4,182.9 3,566.8 3,099.6 3,035.1 2,875.3

Capital expenditures $1,246.7 1,296.4 1,163.7 1,035.9 987.1 993.6

Cash dividends declared per common share $.98 .94 .84 .76 .68 .60

Common shares outstanding (in thousands) 1,564,518 1,563,068 1,554,530 1,545,934 1,547,020 1,530,672

Number of common shareholders 91,212 94,687 97,760 101,272 106,766 109,864

Number of employees 72,181 71,819 71,426 60,571 57,100 56,510

Sales per employee (in dollars) $272,656 246,239 228,000 226,939 230,782 221,425

Market price per share high $47.15 58.00 57.17 56qf 53516 50116

Market price per share low $33.75 29.80 42.00 29ek 33 32qs

Market price per share close $46.60 40.00 55.75 48716 36516 49

Six-Year Financial Summary(dollars in millions except per share data)

(1) In 2002, Abbott also recorded a pretax charge of $108 for acquired in-process research and development related to the

acquisitions of the cardiovascular stent business of Biocompatibles International plc, certain cardiovascular stent technology

rights from Medtronic, Inc. and an additional interest of the issued common shares of Hokuriku Seiyaku Co., Ltd. In 2001,

Abbott also recorded a pretax charge of $1,330 for acquired-in-process research and development related to the acquisitions

of the pharmaceutical business of BASF and of Vysis, Inc.

28 29

Abbott Park, IllinoisAbingdon, EnglandAlameda, CaliforniaAltavista, VirginiaAustin, TexasBarceloneta, Puerto RicoBeringen, SwitzerlandBrockville, CanadaBuenos Aires, ArgentinaCampoverde, ItalyCasa Grande, ArizonaCimangis, IndonesiaColumbus, OhioCootehill/Finisklin, IrelandCoyoacan, MexicoDainabot, JapanDallas, TexasDartford, EnglandDelkenheim, GermanyDowners Grove, IllinoisEast Windsor, New Jersey Galway, IrelandGlen Falls, New YorkGoa, IndiaGranada, SpainIrving, Texas

Jayuya, Puerto RicoJohannesburg, South AfricaKanata, OntarioKarachi, PakistanKatsuyama, JapanLiestal, SwitzerlandLongford, IrelandLudwigshafen, GermanyMatsudo, JapanMexico City, MexicoNorth Chicago, IllinoisQueenborough, England Rangendingen, GermanyRedwood City, CaliforniaRio de Janeiro, BrazilSanta Clara, CaliforniaShanghai, ChinaSouth Pasadena, CaliforniaSturgis, MichiganSt. Remy, FranceWhippany, New JerseyWitney, EnglandWorcester, MassachusettsWyandotte, Michigan Zwolle, The Netherlands

Directors

Senior ManagementPlant Locations

Corporate Officers

Miles D.WhiteChairman of the Board andChief Executive Officer

Richard A. GonzalezPresident and Chief Operating Officer,Medical Products Group

Jeffrey M. Leiden, M.D., Ph.D.President and Chief Operating Officer,Pharmaceutical Products GroupChief Scientific Officer

Richard W. AshleyExecutive Vice President,Corporate Development

Jose M. de LasaExecutive Vice President,Secretary and General Counsel

Thomas C. FreymanExecutive Vice President,Finance and Chief Financial Officer

William G. DempseySenior Vice President,Pharmaceutical Operations

Holger LiepmannSenior Vice President,International Operations

Gary E. McCulloughSenior Vice President,Ross Products

Joseph M. NemmersSenior Vice President,Diagnostics Operations

Thomas M.WascoeSenior Vice President,Human Resources

Lance B.WyattSenior Vice President,Global PharmaceuticalManufacturing

The companys corporate offices are located at 100 Abbott Park Road, Abbott Park,Illinois 60064-6400. The locations of the companys major plants are listed below.

Roxanne S. AustinFormer President and Chief Operating Officer,DIRECTV, Inc.El Segundo, Calif.

H. Laurance FullerRetired Co-Chairman of the Board,BP Amoco plcLondon, United Kingdom

Richard A. GonzalezPresident and Chief Operating Officer,Medical Products Group,Abbott Laboratories

Jack M. GreenbergRetired Chairman and Chief Executive Officer,McDonalds CorporationOak Brook, Ill.

Jeffrey M. Leiden, M.D., Ph.D.President and Chief Operating Officer,Pharmaceutical Products Group,Chief Scientific Officer,Abbott Laboratories

The Rt. Hon. Lord Owen CHExecutive Chairman ofGlobal Natural Energy plcLondon, United Kingdom

Boone Powell Jr.Retired Chairman,Baylor Health Care SystemDallas, Texas

Addison Barry RandChairman and Chief Executive Officer,Equitant Stamford, Conn.

W. Ann Reynolds, Ph.D.Retired Director, Center for CommunityOutreach and Development,The University of Alabama at BirminghamBirmingham, Ala.

Roy S. RobertsManaging Director,Reliant Equity InvestorsChicago, Ill.Retired Group Vice President,North American Vehicle Sales,Service and Marketing,General Motors Corp.Detroit, Mich.

William D. SmithburgRetired Chairman, President and ChiefExecutive Officer,The Quaker Oats Co.Chicago, Ill.

John R.WalterRetired President and Chief Operating Officer,AT&T Corp.Basking Ridge, N.J.;Former Chairman andChief Executive Officer,R. R. Donnelley & Sons Co.Chicago, Ill.

Miles D.WhiteChairman of the Boardand Chief Executive Officer,Abbott Laboratories

Catherine V. BabingtonVice President, InvestorRelations and Public Affairs

Michael G. Beatrice, Ph.D.Vice President,Corporate Regulatory andQuality Science

Jeffrey R. BinderVice President,Spinal Concepts

Olivier BohuonVice President,European Operations

Charles M. BrockVice President, Chief Ethicsand Compliance Officer

William E. Brown III, Ph.D.Vice President,Diagnostic Assays and Systems Development

Douglas C. BryantVice President,Global CommercialOperations, Diagnostics

Thomas F. ChenVice President, Pacific, Asiaand Africa Operations

Michael J. CollinsVice President,Diagnostic CommercialOperations, U.S.

Jaime ContrerasVice President, DiagnosticCommercial Operations,Europe, Africa and the Middle East

Thomas J. DeeVice President, Internal Audit

Edward J. FiorentinoVice President and President,MediSense

Stephen R. FussellVice President, Compensationand Development

Mark F. GormanVice President, Ross Products,Medical Nutritionals

Robert B. HanceVice President and President,Vascular Devices

James J. Koziarz, Ph.D.Vice President, Hep/RetroR&D and Assay TechnicalSupport, Diagnostics

John C. LandgrafVice President, QualityAssurance and Compliance,Medical Products Group

Elaine R. LeavenworthVice President,Government Affairs

Gerald LemaVice President, DiagnosticCommercial Operations,Asia and Pacific

John M. Leonard, M.D.Vice President, GlobalPharmaceutical Development

Greg W. LinderVice President and Controller

Richard J. MarascoVice President,Ross Products, Pediatrics

Heather L. MasonVice President, PharmaceuticalProducts, Specialty Operations

P. Loreen MershimerVice President, HospitalProducts Business Sector

Edward L. MichaelVice President and President,Molecular Diagnostics

Karen L. MillerVice President,Information Technology

Sean E. MurphyVice President,Global Licensing/New Business Development

Daniel W. Norbeck, Ph.D.Vice President, GlobalPharmaceutical Discovery

D. Stafford OKellyVice President,Latin America and Canada

Laura J. SchumacherVice President, Secretary andDeputy General Counsel

AJ J. ShoultzVice President, Taxes

Mary T. SzelaVice President,Pharmaceutical Products,Primary Care Operations

James L. TyreeVice President,Global Licensing/New Business Development

H. Thomas Watkins*President, TAPPharmaceutical Products Inc.

Susan M.WidnerVice President,Corporate Marketing

*Officer of joint venture

Abbott Laboratories100 Abbott Park Road, Abbott Park, IL 60064-6400 U.S.A.

(847) 937-6100 www.abbott.com

a

Published by Abbotts Investor Relations/Public Affairs Division.Corporate Public Affairs (847) 937-1608 Investor Newsline (847) 937-7300

The ticker symbol for Abbott Laboratories common stock is ABT.It is listed on the New York, Chicago, Pacific, London and Swiss exchanges.

It is traded on the Boston, Cincinnati and Philadelphia exchanges.

On the cover: Chicago native, Tecela Harris, first experienced symptoms of rheumatoid arthritis at her senior prom, when pain in her

joints was unbearable. After 18 years of trying numerous medicines without improvement, Tecela was prescribed Humira. With just

two injections, she experienced a dramatic improvement and has energy again working full time, spending time with her husband, caring

for her newborn son, and taking walks with her father.

Abbott trademarks and products in-licensed by Abbott are shown in italics in the text of this Fact Book.

Not all products listed are approved in all countries.

2004, Abbott Laboratories 100M/5/04